Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy

doi:10.1002/mds.27778

Editorial

. 2019 Aug;34(8):1087-1088.

doi: 10.1002/mds.27778.

Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy

Maria Stamelou^{1

2

3}

Affiliations

¹ Parkinson's Disease and Movement Disorders Department, HYGEIA Hospital, Athens, Greece.
² First Department of Neurology, Aiginiteion Hospital, National and Kapodistrian University of Athens, Athens, Greece.
³ Neurology Clinic, Philipps-University, Marburg, Germany.

PMID: 31424622
DOI: 10.1002/mds.27778

Editorial

Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy

Maria Stamelou. Mov Disord. 2019 Aug.

. 2019 Aug;34(8):1087-1088.

doi: 10.1002/mds.27778.

Author

Maria Stamelou^{1

2

3}

Affiliations

¹ Parkinson's Disease and Movement Disorders Department, HYGEIA Hospital, Athens, Greece.
² First Department of Neurology, Aiginiteion Hospital, National and Kapodistrian University of Athens, Athens, Greece.
³ Neurology Clinic, Philipps-University, Marburg, Germany.

PMID: 31424622
DOI: 10.1002/mds.27778

No abstract available

Keywords: criteria; diagnosis; progressive supranuclear palsy; therapeutics.

PubMed Disclaimer

Comment on

Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.
Ali F, Martin PR, Botha H, Ahlskog JE, Bower JH, Masumoto JY, Maraganore D, Hassan A, Eggers S, Boeve BF, Knopman DS, Drubach D, Petersen RC, Dunkley ED, van Gerpen J, Uitti R, Whitwell JL, Dickson DW, Josephs KA. Ali F, et al. Mov Disord. 2019 Aug;34(8):1144-1153. doi: 10.1002/mds.27619. Epub 2019 Feb 6. Mov Disord. 2019. PMID: 30726566 Free PMC article.

Cited by

Exercise and physical activity for people with Progressive Supranuclear Palsy: a systematic review.
Slade SC, Finkelstein DI, McGinley JL, Morris ME. Slade SC, et al. Clin Rehabil. 2020 Jan;34(1):23-33. doi: 10.1177/0269215519877235. Epub 2019 Sep 27. Clin Rehabil. 2020. PMID: 31559853 Free PMC article.

References

1. Giagkou N, Stamelou M. Emerging drugs for progressive supranuclear palsy. Expert Opin Emerg Drugs 2019; https://doi.org/10.1080/14728214.2019.160945.
1. Respondek G, Roeber S, Kretzschmar H, et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 2013;28:504-509.
1. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 2017;32:853-864.
1. Respondek G, Kurz C, Arzberger T, et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 2017;32:995-1005.
1. Whitwell JL, Höglinger GU, Antonini A, et al. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord 2017;32:955-971.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

[1] Giagkou N, Stamelou M. Emerging drugs for progressive supranuclear palsy. Expert Opin Emerg Drugs 2019; https://doi.org/10.1080/14728214.2019.160945.

[2] Giagkou N, Stamelou M. Emerging drugs for progressive supranuclear palsy. Expert Opin Emerg Drugs 2019; https://doi.org/10.1080/14728214.2019.160945.

[3] Respondek G, Roeber S, Kretzschmar H, et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 2013;28:504-509.

[4] Respondek G, Roeber S, Kretzschmar H, et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 2013;28:504-509.

[5] Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 2017;32:853-864.

[6] Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 2017;32:853-864.

[7] Respondek G, Kurz C, Arzberger T, et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 2017;32:995-1005.

[8] Respondek G, Kurz C, Arzberger T, et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 2017;32:995-1005.

[9] Whitwell JL, Höglinger GU, Antonini A, et al. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord 2017;32:955-971.

[10] Whitwell JL, Höglinger GU, Antonini A, et al. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? Mov Disord 2017;32:955-971.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy

Affiliations

Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy

Author

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical